Autolus Therapeutics plc 8-K

What Happened
Autolus Therapeutics plc announced its financial results for the quarter ended March 31, 2026 and provided a corporate update in an 8-K filed May 14, 2026. The company furnished a press release (Exhibit 99.1) and an updated corporate presentation used in its May 14, 2026 conference call (Exhibit 99.2); both exhibits are incorporated by reference in the filing. The report was signed by CEO Christian Itin, Ph.D.

Key Details

• Filing date: May 14, 2026; reporting period: quarter ended March 31, 2026.
• Exhibit 99.1 — press release announcing the quarter’s results and corporate update.
• Exhibit 99.2 — updated corporate presentation used for the May 14, 2026 conference call (Regulation FD disclosure).
• Form 8-K signed by CEO Christian Itin, Ph.D.

Why It Matters
This 8-K signals that Autolus has released its quarterly earnings and provided an investor-facing update; retail investors should review the attached press release and presentation for the material financial details (revenue, net income/loss, cash runway) and any program or guidance updates discussed on the May 14 conference call. The Regulation FD disclosure indicates the company distributed updated investor materials publicly at the time of the call.